sepsis with concomitant cardiac dysfunction
Conditions
Interventions
recombinant human brain natriuretic peptide group:None
Sponsors
The Second Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Age 18–85 years; 2.Meeting the Sepsis-3 diagnostic criteria [defined as an increase of 2 points or more in the Sequential Organ Failure Assessment (SOFA) score from baseline in the context of infection]; 3.Presence of cardiac dysfunction during the course of sepsis treatment, regardless of a prior history of acute or chronic heart failure, with New York Heart Association (NYHA) functional class III or IV; 4.Signed informed consent obtained from the patient or their legally authorized representative (patients may be enrolled first in emergency situations and consent obtained thereafter);
Exclusion criteria
Exclusion criteria: 1.Known allergy to any component of recombinant human brain natriuretic peptide (rhBNP, brand name: Xinhuosu); 2.Presence of cardiogenic shock or systolic blood pressure < 90 mmHg (patients are eligible if the condition has improved and blood pressure has reached the target level after treatment, provided that the clinical course is clearly documented in the medical records); 3.Special populations, including those with significant valvular stenosis, hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, or cardiac tamponade; 4.Suspected or confirmed low cardiac filling pressure; 5.End-stage renal disease requiring regular long-term dialysis; 6.Pregnant or breastfeeding women; 7.Expected survival < 24 hours (e.g., irreversible severe brain injury); 8.Refusal to participate in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of Sequential Organ Failure;Changes in the Acute Physiology and Chronic Health Evaluation (APACHE II) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Degree of haemodynamic improvement; | — |
Countries
China
Contacts
Public ContactGan Weini
The Second Affiliated Hospital of Guangxi Medical University
Outcome results
None listed